CNSA Plain Language Summary Template Cohen Mar 21.pptx (215.79 kB)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-adjusted Indirect Comparison

media

posted on 2021-05-11, 21:09 authored by Stanley Cohan, Jinender Kumar, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic, Tom Tencer

The above plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s40263-021-00805-0

Usage metrics

Read the peer-reviewed publication

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-adjusted Indirect Comparison

CNS Drugs

Keywords

Multiple Sclerosis Ozanimod dimethyl fumarate (DMF)Matching adjusted indirect comparison Systematic Review Plain Language Summary

Licence

CC BY-NC 4.0

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-adjusted Indirect Comparison

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports